MIF: Mood Improving/Inhibiting Factor?

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Bloom, Joshua ^a,b   Al Abed, Yousef ^b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Antidepressant; Biomarker; Depression; MIF; Neurogenesis; Neuroinflammation

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CORTICOSTEROID; CORTICOSTERONE; CORTICOTROPIN; ESCITALOPRAM; FLUOXETINE; GLUCOCORTICOID; HYDROCORTISONE; MIGRATION INHIBITION FACTOR; NORTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE 2;

ADD ON THERAPY; ANTIDEPRESSANT ACTIVITY; BRAIN DEPTH STIMULATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; REVIEW;

ANIMALS; CENTRAL NERVOUS SYSTEM; DEPRESSION; GLUCOCORTICOIDS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS;

EID: 84892576514     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-11     Document Type: Review

References (91)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 2013, Washington DC: American Psychiatric Association, 5, American Psychiatric Association.
2. Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, Stein DJ, Zaslavsky AM, Aguilar-Gaxiola S, Alonso J, Andrade L, Benjet C, de Girolamo G, de Graaf R, Demyttenaere K, Fayyad J, Haro JM, Hu CY, Karam A, Lee S, Lepine J-P, Matchsinger H, Mihaescu-Pintia C, Posada-Villa J, Sagar R, Ustün TB. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry 2011, 68:90-100. 10.1001/archgenpsychiatry.2010.180, 3057480, 21199968.
3. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, de Graaf R, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Ustün TB, Wittchen H-U. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res 2003, 12:3-21. 10.1002/mpr.138, 12830306.
4. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627. 10.1001/archpsyc.62.6.617, 2847357, 15939839.
5. Cowen PJ. Classification of depressive disorders. Curr Top Behav Neurosci 2013, 14:3-13.
6. Kravitz RL, Ford DE. Introduction: chronic medical conditions and depression - the view from primary care. Am J Med 2008, 121:S1-S7.
7. Katon W, Fan M-Y, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med 2008, 23:1571-1575. 10.1007/s11606-008-0731-9, 2533367, 18649108.
8. Biringer E, Mykletun A, Sundet K, Kroken R, Stordal KI, Lund A. A longitudinal analysis of neurocognitive function in unipolar depression. J Clin Exp Neuropsychol 2007, 29:879-891. 10.1080/13803390601147686, 17852600.
9. Martínez-Arán A, Vieta E, Colom F, Torrent C, Sánchez-Moreno J, Reinares M, Benabarre A, Goikolea JM, Brugué E, Daban C, Salamero M. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004, 6:224-232. 10.1111/j.1399-5618.2004.00111.x, 15117401.
10. Behnken A, Schöning S, Gerss J, Konrad C, de Jong-Meyer R, Zwanzger P, Arolt V. Persistent non-verbal memory impairment in remitted major depression - caused by encoding deficits?. J Affect Disord 2010, 122:144-148. 10.1016/j.jad.2009.07.010, 19692126.
11. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40. 10.1176/appi.ajp.163.1.28, 16390886, STAR*D Study Team.
12. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008, 455:894-902. 10.1038/nature07455, 2721780, 18923511.
13. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of six-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69:572-579. 3371295, 22393205.
14. Anisman H, Hayley S. Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal 2012, 5:pe45-pe45.
15. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56. 10.1038/nrn2297, 2919277, 18073775.
16. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741. 10.1016/j.biopsych.2008.11.029, 2680424, 19150053.
17. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160:1554-1565. 10.1176/appi.ajp.160.9.1554, 12944327.
18. Dobos N, de Vries EFJ, Kema IP, Patas K, Prins M, Nijholt IM, Dierckx RA, Korf J, den JA B, Luiten PGM, Eisel ULM. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis 2012, 28:905-915.
19. Savaskan NE, Fingerle-Rowson G, Buchfelder M, Eyüpoglu IY. Brain miffed by macrophage migration inhibitory factor. Int J Cell Biol 2012, 2012:1-11.
20. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800. 10.1038/nri1200, 14502271.
21. Flaster H, Bernhagen J, Calandra T, Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007, 21:1267-1280. 10.1210/me.2007-0065, 17389748.
22. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000, 408:211-216. 10.1038/35041591, 11089976.
23. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000, 6:164-170. 10.1038/72262, 10655104.
24. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002, 4:449-460. 10.1016/S1286-4579(02)01560-5, 11932196.
25. Das R, Koo MS, Kim BH, Jacob ST. Macrophage Migration Inhibitory Factor (MIF) is a critical mediator of the innate immune response to mycobacterium tuberculosis. Proc Natl Acad Sci USA 2013, 110(32):E2997-E3006. 10.1073/pnas.1301128110, 23882081.
26. Toso C, Emamaullee JA, Merani S, Shapiro AMJ. The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. Diabetologia 2008, 51:1937-1946. 10.1007/s00125-008-1063-3, 18612626.
27. Leng L, Bucala R. Insight into the biology of macrophage migration inhibitory factor (MIF) revealed by the cloning of its cell surface receptor. Cell Res 2006, 16:162-168. 10.1038/sj.cr.7310022, 16474429.
28. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999, 274:18100-18106. 10.1074/jbc.274.25.18100, 10364264.
29. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001, 414:920-924. 10.1038/414920a, 11780066.
30. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999, 190:1375-1382. 10.1084/jem.190.10.1375, 2195698, 10562313.
31. Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, Rorsman H. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 1996, 2:143-149. 2230029, 8900542.
32. Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Jüttner S, Brunner H, Bernhagen J. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 1998, 280:85-102. 10.1006/jmbi.1998.1864, 9653033.
33. Nishibori M, Nakaya N, Tahara A, Kawabata M, Mori S, Saeki K. Presence of macrophage migration inhibitory factor (MIF) in ependyma, astrocytes and neurons in the bovine brain. Neurosci Lett 1996, 213:193-196.
34. Ogata A, Nishihira J, Suzuki T, Nagashima K, Tashiro K. Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci Lett 1998, 246:173-177. 10.1016/S0304-3940(98)00203-1, 9792620.
35. Bacher M, Meinhardt A, Lan HY, Dhabhar FS, Mu W, Metz CN, Chesney JA, Gemsa D, Donnelly T, Atkins RC, Bucala R. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998, 4:217-230. 2230367, 9606175.
36. Conboy L, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra T, Lashuel HA, Sandi C. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry 2010, 16:533-547.
37. Matsunaga J. Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 1999, 274:3268-3271. 10.1074/jbc.274.6.3268, 9920865.
38. Solano F, Hearing VJ, García-Borrón JC. Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification. Neurotox Res 2000, 1:153-169.
39. Rao K, Hegde M, Anitha S, Musicco M, Zucca F, Turro N, Zecca L. Amyloid β and neuromelanin - toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol 2006, 78:364-373. 10.1016/j.pneurobio.2006.03.004, 16682109.
40. Kithcart AP, Cox GM, Sielecki T, Short A, Pruitt J, Papenfuss T, Shawler T, Gienapp I, Satoskar AR, Whitacre CC. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J 2010, 24:4459-4466. 10.1096/fj.10-162347, 2974415, 20624927.
41. Chen Y, Wu X, Yu S, Lin X, Wu J, Li L, Zhao J, Zhao Y. Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS ONE 2012, 7:e40165. 10.1371/journal.pone.0040165, 3387137, 22768247.
42. Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N. Identification of the cortical neurons that mediate antidepressant responses. Cell 2012, 149:1152-1163. 10.1016/j.cell.2012.03.038, 3397430, 22632977.
43. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008, 213:93-118. 10.1007/s00429-008-0189-x, 2522333, 18704495.
44. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest 2009, 119:717-725. 10.1172/JCI38454, 2662569, 19339763.
45. Ling J, Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer Lett 2012, 322:119-126. 10.1016/j.canlet.2012.02.033, 22433713.
46. Roviezzo F, Getting SJ, Paul-Clark MJ, Yona S, Gavins FNE, Perretti M, Hannon R, Croxtall JD, Buckingham JC, Flower RJ. The annexin-1 knockout mouse: what it tells us about the inflammatory response. J Physiol Pharmacol 2002, 53:541-553.
47. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002, 22:7802-7811. 10.1128/MCB.22.22.7802-7811.2002, 134716, 12391149.
48. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 1997, 17:6274-6282. 232478, 9343388.
49. Baugh JA, Donnelly SC. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 2003, 179:15-23. 10.1677/joe.0.1790015, 14529561.
50. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 1996, 10:1607-1613.
51. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71. 10.1038/377068a0, 7659164.
52. Kathol RG, Jaeckle RS, Lopez JF, Meller WH. Pathophysiology of HPA axis abnormalities in patients with major depression: an update. Am J Psychiatry 1989, 146:311-317.
53. Pariante CM, Nemeroff CB, Miller AH. Glucocorticoid receptors in depression. Isr J Med Sci 1995, 31:705-712.
54. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 2003, 43:60-66. 10.1016/S0018-506X(02)00016-8, 12614635.
55. Brown ES, Varghese FP, McEwen BS. Association of depression with medical illness: does cortisol play a role?. Biol Psychiatry 2004, 55:1-9.
56. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998, 21:293-307. 10.1016/S0193-953X(05)70006-X, 9670227.
57. Neigh GN, Nemeroff CB. Reduced glucocorticoid receptors: consequence or cause of depression?. Trends Endocrinol Metab 2006, 17:124-125. 10.1016/j.tem.2006.03.002, 16574425.
58. Joëls M, Karst H, Krugers HJ, Lucassen PJ. Chronic stress: implications for neuronal morphology, function and neurogenesis. Front Neuroendocrinol 2007, 28:72-96. 10.1016/j.yfrne.2007.04.001, 17544065.
59. Edwards KM, Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Elevated macrophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav Immun 2010, 24:1202-1208. 10.1016/j.bbi.2010.03.011, 20382217.
60. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245. 10.1016/S0165-6147(02)02017-5, 12008002.
61. Berton O, Hahn CG, Thase ME. Are we getting closer to valid translational models for major depression?. Science 2012, 338:75-79. 10.1126/science.1222940, 23042886.
62. Perez-Caballero L, Rez-Egea RPE, Romero-Grimaldi C, Puigdemont D, Molet J, Caso J-R, Mico J-A, Rez VPE, Leza J-C, Berrocoso E. Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol Psychiatry 2013, 1-8. doi:10.1038/mp.2013.63.
63. Gourley SL, Wu FJ, Kiraly DD, Ploski JE, Kedves AT, Duman RS, Taylor JR. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008, 63:353-359. 10.1016/j.biopsych.2007.07.016, 2277331, 17889834.
64. Al-Abed Y, VanPatten S. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem 2011, 3:45-63. 10.4155/fmc.10.281, 21428825.
65. Baune BT. Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry 2013, 1-27. doi:10.3389/fpsyt.2013.00003.
66. Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl) 2011, 219:687-698.
67. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996, 8:666-676. 10.1111/j.1460-9568.1996.tb01252.x, 9081618.
68. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005, 6:484-494. 10.1038/nrn1687, 15928718.
69. Moon HY, Kim SH, Yang YR, Song P, Yu HS, Park HG, Hwang O, Lee-Kwon W, Seo JK, Hwang D, Choi JH, Bucala R, Ryu SH, Kim YS, Suh P-G. Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci USA 2012, 109:13094-13099. 10.1073/pnas.1205535109, 3420190, 22826223.
70. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22:3251-3261.
71. Gutknecht L, Waider J, Kraft S, Kriegebaum C, Holtmann B, Reif A, Schmitt A, Lesch K-P. Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice. J Neural Transm 2008, 115:1127-1132. 10.1007/s00702-008-0096-6, 18665319.
72. Swant JD. Rho GTPase-dependent signaling is required for macrophage migration inhibitory factor-mediated expression of cyclin D1. J Biol Chem 2005, 280:23066-23072. 10.1074/jbc.M500636200, 1201442, 15840582.
73. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330. 10.1016/0092-8674(95)90385-2, 7736585.
74. Ito K, Yoshiura Y, Ototake M, Nakanishi T. Macrophage migration inhibitory factor (MIF) is essential for development of zebrafish, Danio rerio. Dev Comp Immunol 2008, 32:664-672. 10.1016/j.dci.2007.10.007, 18068224.
75. Wistow GJ, Shaughnessy MP, Lee DC, Hodin J, Zelenka PS. A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc Natl Acad Sci USA 1993, 90:1272-1275. 10.1073/pnas.90.4.1272, 45854, 7679497.
76. Kobayashi S, Satomura K, Levsky JM, Sreenath T, Wistow GJ, Semba I, Shum L, Slavkin HC, Kulkarni AB. Expression pattern of macrophage migration inhibitory factor during embryogenesis. Mech Dev 1999, 84:153-156. 10.1016/S0925-4773(99)00057-X, 10473131.
77. Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M, Nishihira J. Augmented expression of macrophage migration inhibitory factor (MIF) in the telencephalon of the developing rat brain. Brain Res 1999, 816:457-462. 10.1016/S0006-8993(98)01179-2, 9878869.
78. Ohta S, Misawa A, Fukaya R, Inoue S, Kanemura Y, Okano H, Kawakami Y, Toda M. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012, 125:3210-3220. 10.1242/jcs.102210, 22454509.
79. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457. 10.1016/j.biopsych.2009.09.033, 20015486.
80. Lu XT, Liu YF, Zhao L, Li WJ, Yang RX, Yan FF, Zhao YX, Jiang F. Chronic psychological stress induces vascular inflammation in rabbits. Stress 2013, 16:87-98. 10.3109/10253890.2012.676696, 22428781.
81. Hawkley LC, Bosch AJ, Engeland GC, Marucha TP, Cacioppo TJ. Cytokines 2006, Boca Raton, FL: CRC Press, 33487-2742.
82. Christian LM, Franco A, Iams JD, Sheridan J, Glaser R. Depressive symptoms predict exaggerated inflammatory responses to an in vivo immune challenge among pregnant women. Brain Behav Immun 2010, 24:49-53. 10.1016/j.bbi.2009.05.055, 2787729, 19464358.
83. Katsuura S, Kamezaki Y, Yamagishi N, Kuwano Y, Nishida K, Masuda K, Tanahashi T, Kawai T, Arisawa K, Rokutan K. Circulating vascular endothelial growth factor is independently and negatively associated with trait anxiety and depressive mood in healthy Japanese university students. Int J Psychophysiol 2011, 81:38-43. 10.1016/j.ijpsycho.2011.04.004, 21545819.
84. Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci 2013, 14:135-151.
85. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression - No influence of celecoxib treatment. J Affect Disord 2011, 134:217-225. 10.1016/j.jad.2011.05.047, 21684012.
86. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'Predictors' and longitudinal 'Targets'. Neuropsychopharmacology 2012, 38:377-385. 3547188, 22990943.
87. Bacher M, Weihe E, Dietzschold B, Meinhardt A, Vedder H, Gemsa D, Bette M. Borna disease virus-induced accumulation of macrophage migration inhibitory factor in rat brain astrocytes is associated with inhibition of macrophage infiltration. Glia 2002, 37:291-306. 10.1002/glia.10013, 11870869.
88. Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, Bucala R. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 2007, 117:3059-3066. 10.1172/JCI32218, 1994625, 17909632.
89. Kyhos B, Spak D. Baxter initiates phase I clinical trial with anti-MIF antibody in patients with solid tumors. 2012, 1-2. http://www.baxter.com/press_room/press_releases/2012/09_05_12_anti-mif.html.
90. Schneider B, Prvulovic D. Novel biomarkers in major depression. Curr Opin Psychiatry 2013, 26:47-53. 10.1097/YCO.0b013e32835a5947, 23154643.
91. Pandya M, Altinay M, Malone DA, Anand A. Where in the brain is depression?. Curr Psychiatry Rep 2012, 14:634-642. 10.1007/s11920-012-0322-7, 3619732, 23055003.